keyword
MENU ▼
Read by QxMD icon Read
search

apatinib

keyword
https://www.readbyqxmd.com/read/29225166/apatinib-inhibits-migration-and-invasion-as-well-as-pd-l1-expression-in-osteosarcoma-by-targeting-stat3
#1
Bingxin Zheng, Tingting Ren, Yi Huang, Wei Guo
The cure rate of osteosarcoma has not improved in the past 30 years. The new treatments and drugs is urgently needed, especially for metastatic osteosarcoma. Anti-angiogenesis therapy and immunotherapy has got promising anti-tumor effects in various tumors. It is hypothesised that combining checkpoint inhibitor immunotherapies with antiangiogenic treatment may have a synergistic effect and enhance the efficacy of both treatments. However, its underlying mechanism remain largely uninvestigated. To investigate the clinical significance of vascular endothelial growth factor receptor-2 (VEGFR2) and programmed death ligand-1 (PD-L1) in osteosarcoma, we analyzes their expression levels in 93 osteosarcoma specimens by immunohistochemistry...
December 7, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29215372/efficacy-and-safety-of-apatinib-as-second-line-therapy-for-advanced-gastric-cancer-a-single-center-observational-study
#2
Yong Zhang, Miaomiao Gou, Chun Han, Juan Li, Lijie Wang, Qian Qiao, Yi Hu, Li Bai, Zhefeng Liu
Apatinib has been proven to be effective and safe among patients in the third-line treatment of advanced gastric cancer in phase II and III trials. We aimed to evaluate its efficacy and safety in second-line practice, and to explore the factors associated with efficacy. Between April 2015 and May 2017, a total of 23 patients with advanced gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction were enrolled and followed up retrospectively after failing the first line of systemic therapy. The median progression-free survival was 4...
December 5, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29190616/apatinib-inhibits-angiogenesis-via-suppressing-akt-gsk3%C3%AE-ang-signaling-pathway-in-anaplastic-thyroid-cancer
#3
Zhijian Jin, Xi Cheng, Haoran Feng, Jie Kuang, Weiping Yang, Chenghong Peng, Baiyong Shen, Weihua Qiu
BACKGROUND/AIMS: Anaplastic thyroid carcinoma (ATC) is one of the most lethal human malignancies, and there is no efficient method to slow its process. Apatinib, a novel tyrosine kinase inhibitor (TKI), has been confirmed for its efficacy and safety in the treatment of advanced gastric carcinoma patients. However, the effects of Apatinib in ATC are still unknown. METHODS: In this study, we explored the effects and mechanisms of Apatinib on tumor growth and angiogenesis in vitro and in vitro in ATC cells...
December 1, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29167006/-efficacy-and-survival-analysis-of-apatinib-in-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer-after-failure-of-first-line-treatment
#4
Xuemin Wang, Weihong Zhang, Weijiao Du, Xinwei Zhang, Xiubao Ren, Shui Cao
BACKGROUND: The efficacy of second or third-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients is low. The use of targeted drugs brings survival benefit for some patients. Apatinib, as a novel small molecule antiangiogenic drug, has demonstrated satisfactory anticancer activity across a broad range of malignancies. The aim of this study is to evaluate the efficacy and safety of apatinib in patients with advanced NSCLC after first-line treatment failure. METHODS: A retrospective study of 128 patients was conducted to evaluate the safety, short-term efficacy and survival status with different regimens...
November 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29151702/extraordinary-response-of-metastatic-pancreatic-cancer-to-apatinib-after-failed-chemotherapy-a-case-report-and-literature-review
#5
Cheng-Ming Li, Zhi-Chao Liu, You-Ting Bao, Xin-Dong Sun, Lin-Lin Wang
Chemotherapy has limited efficacy in the treatment of advanced and metastatic pancreatic cancer (PC), and has serious side effects. The development of novel effective agents, especially targeted therapy, is essential for patients with PC. We present a 58-year-old Chinese woman initially diagnosed with locally advanced PC. As the disease progressed to Stage IV, the patient was unable to tolerate chemotherapy after the fourth-line treatment. She was then treated with apatinib, a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2 and achieved a progression-free-survival of 7 mo...
November 7, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29145238/apatinib-in-refractory-radiation-induced-brain-edema-a-case-report
#6
Wei Guo Hu, Yi Ming Weng, Yi Dong, Xiang Pan Li, Qi-Bin Song
RATIONALE: Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has observed to be effective and safe in refractory radiation-induced brain edema, like Avastin did. Till now, there is no case report after apatinib came in the market. PATIENT CONCERNS: Two patients who received brain radiotherapy developed clinical manifestations of brain edema, including dizziness, headache, limb activity disorder, and so on...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29142602/combined-aspirin-and-apatinib-treatment-suppresses-gastric-cancer-cell-proliferation
#7
Wei Zhang, Yongsheng Tan, Heping Ma
Gastric cancer (GC), one of the types of tumor most prone to malignancy, is characterized by high lethality. Numerous molecular mediators of GC have been identified, including transcription factors, signaling molecules and non-coding RNAs. Recently, inhibition of angiogenesis has emerged as a potential strategy for GC therapy. In the present study, the levels of vascular endothelial growth factor (VEGF), peroxisome proliferator-activated receptor-α (PPARα) and miR-21 in GC patients and individuals without cancer, and the correlation between VEGF and miR-21, and PPARα and miR-21 expression were analyzed...
November 2017: Oncology Letters
https://www.readbyqxmd.com/read/29141689/patient-derived-xenograft-in-zebrafish-embryos-a-new-platform-for-translational-research-in-gastric-cancer
#8
Jia-Qi Wu, Jing Zhai, Chong-Yong Li, Ai-Min Tan, Ping Wei, Li-Zong Shen, Ming-Fang He
BACKGROUND: Gastric cancer (GC) is among the most commonly cancer occurred in Asian, especially in China. With its high heterogeneity and few of validated drug targets, GC remains to be one of the most under explored areas of precision medicine. In this study, we aimed to establish an in vivo patient-derived xenograft (PDX) model based on zebrafish (Danio rerio) embryos, allowing for a rapid analysis of the angiogenic and invasive potentials, as well as a fast drug sensitivity testing...
November 15, 2017: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/29138576/progression-free-survival-of-up-to-8-months-of-an-advanced-intrahepatic-cholangiocarcinoma-patient-treated-with-apatinib-a-case-report
#9
Fu-Chao Ma, Qian Yu, Zhi-Ming Zeng, Rong-Quan He, Chao-Hua Mo, Jin-Cai Zhong, Jie Ma, Zhen-Bo Feng, Gang Chen, Xiao-Hua Hu
Intrahepatic cholangiocarcinoma (ICC) arises from the biliary epithelium and is a relatively rare and highly fatal neoplasm. The prognosis is poor, and survival is limited to a few months. Here, we report a case of advanced ICC that was successfully treated with apatinib, a new oral tyrosine kinase inhibitor that targets the intracellular domain of vascular endothelial growth factor receptor-2. To the best of our knowledge, this is the first case report of the successful use of apatinib for advanced ICC; this treatment has demonstrated fewer toxic effects than traditional cytotoxic chemotherapy...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29137078/successful-treatment-of-ovarian-cancer-with-apatinib-combined-with-chemotherapy-a-case-report
#10
Mingzi Zhang, Zhongkai Tian, Yehong Sun
RATIONALE: The standard treatment for ovarian cancer is chemotherapy with 2 drugs (taxanes and platinum drugs). However, the traditional combination of the 2 drugs has many adverse effects (AEs) and the cancer cells will quickly become resistant to the drugs. Apatinib is a small-molecule antiangiogenic agent which has shown promising therapeutic effects against diverse tumor types, but it still remains unknown whether apatinib has an antitumor effect in patients with ovarian cancer. Herein, we present a successfully treated case of ovarian cancer using chemotherapy and apatinib, in order to demonstrate the effectiveness of this new combined regimen in ovarian cancer...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29137048/apatinib-for-the-treatment-of-pulmonary-epithelioid-hemangioendothelioma-a-case-report-and-literature-review
#11
Zhipeng Zheng, Hanying Wang, Hanliang Jiang, Enguo Chen, Jun Zhang, Xinyou Xie
RATIONALE: Pulmonary epithelioid hemangioendothelioma (P-EHE) is a rare tumor, with no established standard treatment. Overexpression of vascular endothelial growth factor receptor 2 (VEGFR-2) has been reported in some P-EHE patients. Apatinib, a new small molecule tyrosine kinase inhibitor that specifically targets VEGFR-2, has therapeutic benefits in some advanced tumors. However, its efficacy in P-EHE cases has not been reported. PATIENT CONCERNS: Herein, we presented a 44-year-old man with recurrent hemoptysis for approximately 9 years...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29113769/advanced-scrotal-extramammary-paget-s-disease-treated-with-apatinib-a-case-report
#12
Yun-Ni Zhang, Ye Chen, Feng Gao, Ni Chen, Ji-Yan Liu
No abstract text is available yet for this article.
October 16, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/29075129/apatinib-plus-icotinib-in-treating-advanced-non-small-cell-lung-cancer-after-icotinib-treatment-failure-a-retrospective-study
#13
Jianping Xu, Xiaoyan Liu, Sheng Yang, Xiangru Zhang, Yuankai Shi
BACKGROUND: Treatment failure frequently occurs in patients with epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) who respond to EGFR tyrosine kinase inhibitors initially. This retrospective study tried to investigate the efficacy and safety of apatinib plus icotinib in patients with advanced NSCLC after icotinib treatment failure. PATIENTS AND METHODS: This study comprised 27 patients with advanced NSCLC who had progressed after icotinib monotherapy...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29066909/case-report-of-a-kit-mutated-melanoma-patient-with-an-excellent-response-to-apatinib-and-temozolomide-combination-therapy
#14
Cong Luo, Jiayu Shen, Jieer Ying, Xianhua Fang, Xiaohong Wang, Zhixuan Fu, Peng Liu
Malignant melanoma is one kind of malignant disease which has high rates of mortality, metastasis, and poor prognosis. The therapeutic landscape is rapidly changing with the development of novel agents in recent decades, such as anti-PD-1 agents, anti-CTLA-4 agents, and BRAF inhibitors. However, since most of these novel agents are very expensive, not all patients can afford them. Apatinib is a novel oral small-molecule tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2) and may also be effective on Ret, c-KIT, and c-src...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29038432/efficacy-and-safety-for-apatinib-treatment-in-advanced-gastric-cancer-a-real-world-study
#15
Yong Zhang, Chun Han, Juan Li, Li Zhang, Lijie Wang, Sisi Ye, Yi Hu, Li Bai
Apatinib has been proved to be effective and safe among patients in gastric cancer in Phase II and III Trials. We aimed to evaluate its efficacy and safety in real world practice, and to explore factors associated with efficacy. Between January 2015 and February 2017, totally 36 patients with advanced gastric adenocarcinoma or adenocarcinoma of gastroesophageal junction (GEJ) were enrolled and followed up retrospectively after failing at least two lines of systemic therapy. The mPFS was 2.65 months (95%CI 1...
October 16, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29037469/management-of-patients-with-adenocarcinoma-or-squamous-cancer-of-the-esophagus
#16
David H Ilson, Richard Hillegersberg
Esophageal cancer is characterized by the early and frequent metastasis. Surgery is the primary treatment for early-stage disease, whereas patients with patients with locally advanced disease receive peri-operative chemotherapy or chemoradiotherapy. Squamous cancers can be treated with primary chemoradiotherapy without surgery, depending on their response to therapy and patient tolerance for subsequent surgery. Chemotherapy with a fluorinated pyrimidine and a platinum agent, followed by later treatment with taxanes and irinotecan, provides some benefit...
October 13, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29029508/efficiency-of-low-dosage-apatinib-in-post-first-line-treatment-of-advanced-lung-adenocarcinoma
#17
Da-Xiong Zeng, Chang-Guo Wang, Wei Lei, Jian-An Huang, Jun-Hong Jiang
Chemotherapy is the standard treatment of in advanced lung adenocarcinoma patients without driver mutation. However, few drugs could be selected when diseases progressed after second-line treatment. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), apatinib was suggested mainly using in advanced gastric cancer. In this study, we showed the results of apatinib as second-line to fourth-line treatment in EGFR wild-type advanced lung adenocarcinoma patients. 16 EGFR wild-type advanced lung adenocarcinoma patients were administrated apatinib (250-500 mg/d) orally...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/28969086/efficacy-and-safety-of-apatinib-in-stage-iv-sarcomas-experience-of-a-major-sarcoma-center-in-china
#18
Feng Li, Zhichao Liao, Jun Zhao, Gang Zhao, Xubin Li, Xiaoling Du, Yun Yang, Jilong Yang
PURPOSE: This study was conducted to review the efficacy and safety of Apatinib in stage IV sarcoma patients who failed previous chemotherapy. MATERIALS AND METHODS: The clinical information on 16 patients with stage IV sarcomas who failed in prior chemotherapy and subsequently received Apatinib treatment was collected. Apatinib was given 500mg/daily and 4 weeks as a cycle. All patients had at least one measurable extracranial tumor according to Response Evaluation Criteria In Solid Tumors 1...
September 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28967981/pharmacokinetic-drug-interactions-of-apatinib-with-rifampin-and-itraconazole
#19
Xiaoyun Liu, Yifan Zhang, Qian Chen, Yan Zhan, Quanren Wang, Chaoying Hu, Chen Yu, Zitao Guo, Xiaoyan Chen, Dafang Zhong
Apatinib is a small-molecule tyrosine kinase inhibitor that has been approved for the treatment of patients with advanced-stage gastric cancer or gastroesophageal junction cancer who have progressed or recurred after at least 2 kinds of systemic chemotherapy. In vitro data indicate that cytochrome P450 (CYP) 3A4 is the primary CYP isoenzyme involved in the metabolism of apatinib. Pharmacokinetic drug-drug interactions of apatinib and (1) a CYP3A4 inducer (rifampin) or (2) a CYP3A inhibitor (itraconazole) were clinically evaluated in healthy volunteers...
October 2, 2017: Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28935022/-report-of-successful-treatment-of-a-rectal-cancer-patient-with-endobronchial-%C3%A2-metastasis-by-bronchial-stent-implantation-combined-with-chemotherapy-and-apatinib
#20
Qiuqi Lin, Ling Ding, Cheng Chen, Yehan Zhu
The lungs are the most common sites of metastases from non-pulmonary malignancies. On the other hand, endobronchial metastases are rare. Various tumors have been associated with endobronchial metastasis, most commonly renal, breast and colorectal cancer. Advanced rectal cancerwith lung metastasis is common. However, endobronchial metastasis without lung metastasis of rectal cancer is rare, and easily misdiagnosed. We report one case of postoperative rectal cancer with endobronchial, pleuralcavity, pericardial cavitymetastasis, giving the comprehensive treatment of bronchial stentimplantation, chemotherapy, targeted drugs and remission...
September 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
keyword
keyword
91338
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"